Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.
Moriarty PM, Roth EM, Karns A, Ye P, Zhao SP, Liao Y, Capuzzi DM, Bays HE, Zhang F, Liu S, Reichman AJ, Brusco OA, Lu G, Lerman S, Duan Z, Guo S, Liu PL, Zhao J, Zhang Y, Li S. Moriarty PM, et al. Among authors: zhao j, zhao sp. J Clin Lipidol. 2014 Nov-Dec;8(6):568-575. doi: 10.1016/j.jacl.2014.09.002. Epub 2014 Sep 16. J Clin Lipidol. 2014. PMID: 25499939 Clinical Trial.
Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS).
Zhao SP, Lu ZL, Du BM, Chen Z, Wu YF, Yu XH, Zhao YC, Liu L, Ye HJ, Wu ZH; China Coronary Secondary Prevention Study (CCSPS). Zhao SP, et al. Among authors: zhao yc. J Cardiovasc Pharmacol. 2007 Feb;49(2):81-4. doi: 10.1097/FJC.0b013e31802d3a58. J Cardiovasc Pharmacol. 2007. PMID: 17312447 Clinical Trial.
407 results